Physician profile
Ryan C Denley
NPI 1386038560
$1,262.98
in general payments reported to CMS, 2019-2025
20 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.83 · 2021: $112 · 2022: $12.54 · 2023: $253 · 2024: $464 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $263.13 | 2023-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $128.13 | 2024 | Talvey, Tecvayli |
| Epizyme, INC. | $112.00 | 2021 | |
| Abbvie INC. | $86.49 | 2024 | |
| Merck Sharp & Dohme LLC | $76.80 | 2019-2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $67.64 | 2023-2025 | |
| Tempus Ai, INC | $60.44 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $58.34 | 2025 | Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $58.03 | 2023-2025 | Enhertu |
| Pfizer INC. | $55.50 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $53.13 | 2022-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $44.30 | 2024-2025 | |
| Genentech USA, INC. | $35.75 | 2023 | Columvi, Polivy |
| Adaptive Biotechnologies Corporation | $33.30 | 2024-2025 | Clonoseq |
| Seagen INC. | $29.63 | 2023 | Padcev |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $26.77 | 2023 | Epkinly |
| Janssen Scientific Affairs, LLC | $24.82 | 2024 | Talvey, Tecvayli |
| Stemline Therapeutics INC. | $19.50 | 2023 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $14.76 | 2024 | Imfinzi |
| Array Biopharma INC | $14.52 | 2024 | Tukysa, Mektovi, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Denley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.